Peri-operative anticoagulant effects of heparinization for carotid endarterectomy.
The question of whether or not to reverse heparin following carotid endarterectomy is a topic of debate. The potential reduction of the risk of thrombosis at the endarterectomy site with non-reversal has to be measured against a potential increase in the risk of wound haematoma. This study prospectively followed activated clotting time (ACT) of 42 consecutive patients undergoing carotid endarterectomy. A standard heparin dose of 100 units/kg was used, and heparin reversal was employed only if the wound appeared excessively haemorrhagic at the procedure's completion. Heparin was reversed in 11 patients. Following heparin administration, ACT increased to a mean 2.72 +/- 0.09 times baseline (range 1.84-4.07), and fell with time, until at 3 h after heparin administration mean ACT in the non-reversed patients was 1.48 +/- 0.03 times baseline (range 1.1-2.03). There was one postoperative neurological event (2%), a contralateral hemisphere stroke. No patient developed a frank wound haematoma requiring evacuation, although three patients (7% of the total study group, 9% of patients not receiving heparin reversal) developed neck swelling and symptoms of airway compromise, and were intubated. Measurements of ACT suggest that a heparin dose of 100 units/kg achieves an adequate anticoagulant level in the operative and early postoperative phase, when thrombosis is most likely to occur, and is not associated with an increased risk of wound haematoma. If heparin is to be selectively reversed in patients felt to be at high risk of postoperative haematoma, the decision should be based on an objective measurement such as ACT, and not the surgeon's impression of wound haemostasis.
Coyne
T J
TJ
Division of Neurosurgery, University of Toronto, Ontario, Canada.
Wallace
M C
MC
Benedict
C
C
D000368:Aged; D000369:Aged, 80 and over; D016903:Drug Monitoring; D016894:Endarterectomy, Carotid / Q000009:adverse effects*; D005260:Female; D006406:Hematoma / Q000453:epidemiology / Q000209:etiology; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011479:Protamines / Q000627:therapeutic use; D012307:Risk Factors; D013927:Thrombosis / Q000453:epidemiology / Q000209:etiology; D013997:Time Factors; D014914:Whole Blood Coagulation Time
D011479:Protamines; D006493:Heparin